PRP19 Inhibitors
The chemical class of PRP19 Inhibitors, while not directly targeting PRP19, focuses on influencing either spliceosome function or DNA repair pathways, two primary domains where PRP19 is active. PRP19 is a crucial component in the spliceosome, a complex cellular machine responsible for processing pre-mRNA into mature mRNA, and also has a role in the cellular response to DNA damage.
The majority of the listed inhibitors target the SF3b complex within the spliceosome. Compounds like Pladienolide B, E7107, and Spliceostatin A bind to the SF3b complex, disrupting its normal function and consequently affecting the splicing process where PRP19 is involved. By altering the dynamics or efficiency of splicing, these compounds can indirectly impact PRP19's role in mRNA processing. Additionally, compounds like Camptothecin and the various PARP inhibitors (Olaparib, Niraparib, Rucaparib, Veliparib) affect DNA repair mechanisms. PRP19, aside from its splicing role, is known to participate in the DNA damage response. By targeting proteins involved in DNA repair, these inhibitors can indirectly influence the functions of PRP19 associated with maintaining genomic stability.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $299.00 $5699.00 $11099.00 $25500.00 $66300.00 $2875.00 | 63 | |
Pladienolide B targets the SF3b complex of the spliceosome, potentially influencing PRP19's function in mRNA splicing. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
Spliceostatin A targets the SF3b complex in the spliceosome, potentially influencing PRP19's role in pre-mRNA processing. | ||||||
FR901464 | 146478-72-0 | sc-507352 | 5 mg | $1800.00 | ||
FR901464 targets the spliceosome, potentially affecting PRP19's function in mRNA splicing. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin is a topoisomerase I inhibitor, affecting DNA repair mechanisms. While not directly targeting PRP19, it may indirectly affect its role in DNA repair pathways. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib, a PARP inhibitor, is involved in DNA repair mechanisms. It could indirectly affect PRP19's function in DNA repair, given PRP19's role in this process. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
Niraparib is another PARP inhibitor, potentially influencing DNA repair mechanisms in which PRP19 is involved. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
Rucaparib, a PARP inhibitor, could indirectly influence PRP19's role in DNA repair. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
Veliparib is a PARP inhibitor and may indirectly affect the DNA repair functions involving PRP19. | ||||||